SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
ArQule, Inc. and Daiichi Sankyo, Inc. Announce Completion of Patient Recruitment in Phase 3 Clinical Trial of Tivantinib in Non-Small Cell Lung Cancer